Las Vegas, NV -- (SBWIRE) -- 02/25/2013 -- Advaxis, Inc. (OTC:ADXS) has recently started clinical trials for their vaccine which will be used in the treatment of cervical cancer. However the company faces another direct competition in the specific area of vaccine for cervical cancer. Inovio Pharmaceuticals Inc is also in process of developing such solution.
Advaxis Inc has shown tremendous results in clinical trials of its vaccines. The patients treated with ADXS-HPV showed survival at 12 months which is 33 percent as compared to historical controls of 0-22 percent. It is also reported that almost 17 percent of patients survived at the benchmark of 18th month. The company’s product has shown tremendous reduction in tumor burden and is taken to be more effective than its competitors are building.
Cervical cancer happens to be the second largest reason of death in women in the world almost resulting in 250,000 fatalities around the globe every year. It is estimated that almost $6 billion is spent every year in cervical cancer diagnosis and treatment while almost proceeds of $2.3 billion were generated just from its preventive vaccines in the year 2011.It is also expected that figure of vaccines sales could reach $5.28 billion by the year 2017.
To find out what OTCMAGIC projects for Advaxis Inc for both short term and long term please click here: ADXS
OTCMAGIC Spends all day scouring the markets for the next huge Penny Stock Winner. Investors have come to trust us for our up to date commentary on all hot stocks so please visit OTCMAGIC right now and see what it’s all about for yourself! At 30,000 Visitors a Month and growing rapidly OTCMAGIC is the hottest thing in Penny Stocks!
Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. PLEASE NOTE: OTCMagic.com employees are not registered as an Investment Advisor in any jurisdiction whatsoever. Full disclaimer can be read at http://OTCMagic.com/disclaimer. Release of Liability: Through use of this website viewing or using you agree to hold OTCMagic.com, its operators owners and employees harmless and to completely release them from any and all liability due to any and all loss monetary or otherwise, damage monetary or otherwise, or injury (monetary or otherwise) that you may incur. The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. OTCMagic.com affiliates may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. Any opinions expressed are subject to change without notice. OTCMagic.com encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled, or is available from public sources and OTCMagic.com. We make no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies. This is not a solicitation to buy or sell any securities. Any claims or Statements should be deemed hypothetical. OTCMagic.com, nor any of its affiliates are not registered investment advisors or broker dealers.
Contact Us: 888-4-SBWIRE (US) - 920-321-1250 (International)